Pixantrone-d<sub>8</sub> (maleate)

Pixantrone-d8 (maleate)

CAT N°: 33292
Price:

From 467.00 396.95

Pixantrone-d8 is intended for use as an internal standard for the quantification of pixantrone (Item No. 20055) by GC- or LC-MS. Pixantrone is a DNA topoisomerase II inhibitor.{46348} It induces SV40 DNA cleavage in the presence of mouse topoisomerase II and induces DNA single-strand breaks in NCI H187 cells in a concentration-dependent manner. Pixantrone is cytotoxic to L1210 leukemia cells as well as doxorubicin-sensitive and -resistant LoVo colon adenocarcinoma cells (IC50 = 0.01, 0.24, and 7.2 µg/ml, respectively).{68058} It decreases disease severity in a rat model of myasthenia gravis induced by immunization with the T. californica acetylcholine receptor (AChR) when administered at a dose of 8.12 mg/kg once per week for six weeks.{68059} Formulations containing pixantrone have been used in the treatment of non-Hodgkin B cell lymphoma.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 6,9-bis((2-aminoethyl-1,1,2,2-d4)amino)benzo[g]isoquinoline-5,10-dione, dimaleate
  • Correlated keywords
    • 2012601-54-4 2012601-55-5 BBR 2778 BBR2778 deuterated deuterium GCMS LCMS Torpedo SV-40 NCIH187 H-187 L-1210 nonHodgkin
  • Product Overview:
    Pixantrone-d8 is intended for use as an internal standard for the quantification of pixantrone (Item No. 20055) by GC- or LC-MS. Pixantrone is a DNA topoisomerase II inhibitor.{46348} It induces SV40 DNA cleavage in the presence of mouse topoisomerase II and induces DNA single-strand breaks in NCI H187 cells in a concentration-dependent manner. Pixantrone is cytotoxic to L1210 leukemia cells as well as doxorubicin-sensitive and -resistant LoVo colon adenocarcinoma cells (IC50 = 0.01, 0.24, and 7.2 µg/ml, respectively).{68058} It decreases disease severity in a rat model of myasthenia gravis induced by immunization with the T. californica acetylcholine receptor (AChR) when administered at a dose of 8.12 mg/kg once per week for six weeks.{68059} Formulations containing pixantrone have been used in the treatment of non-Hodgkin B cell lymphoma.

We also advise you